DE60222898D1 - Orlistat und eine fettsäure oder eines ihrer salze enthaltende pharmazeutische zusammensetzung - Google Patents

Orlistat und eine fettsäure oder eines ihrer salze enthaltende pharmazeutische zusammensetzung

Info

Publication number
DE60222898D1
DE60222898D1 DE60222898T DE60222898T DE60222898D1 DE 60222898 D1 DE60222898 D1 DE 60222898D1 DE 60222898 T DE60222898 T DE 60222898T DE 60222898 T DE60222898 T DE 60222898T DE 60222898 D1 DE60222898 D1 DE 60222898D1
Authority
DE
Germany
Prior art keywords
orlistat
salts
pharmaceutical composition
fatty acid
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222898T
Other languages
English (en)
Other versions
DE60222898T2 (de
Inventor
Karsten Maeder
Lukas Christoph Scheibler
Hans Steffen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60222898D1 publication Critical patent/DE60222898D1/de
Publication of DE60222898T2 publication Critical patent/DE60222898T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Position Fixing By Use Of Radio Waves (AREA)
DE60222898T 2001-06-06 2002-05-31 Orlistat und eine fettsäure oder eines ihrer salze enthaltende pharmazeutische zusammensetzung Expired - Lifetime DE60222898T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01113792 2001-06-06
EP01113792 2001-06-06
PCT/EP2002/005958 WO2002098413A2 (en) 2001-06-06 2002-05-31 Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof

Publications (2)

Publication Number Publication Date
DE60222898D1 true DE60222898D1 (de) 2007-11-22
DE60222898T2 DE60222898T2 (de) 2008-07-24

Family

ID=8177653

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60222898T Expired - Lifetime DE60222898T2 (de) 2001-06-06 2002-05-31 Orlistat und eine fettsäure oder eines ihrer salze enthaltende pharmazeutische zusammensetzung

Country Status (21)

Country Link
US (1) US6730319B2 (de)
EP (1) EP1399153B1 (de)
JP (1) JP4558313B2 (de)
KR (1) KR100613946B1 (de)
CN (1) CN1514726B (de)
AR (1) AR037490A1 (de)
AT (1) ATE375155T1 (de)
AU (1) AU2002319189B2 (de)
BR (1) BR0210267A (de)
CA (1) CA2448035C (de)
DE (1) DE60222898T2 (de)
DK (1) DK1399153T3 (de)
ES (1) ES2292782T3 (de)
GT (1) GT200200105A (de)
MX (1) MXPA03011041A (de)
PA (1) PA8546501A1 (de)
PE (1) PE20030262A1 (de)
PT (1) PT1399153E (de)
UY (2) UY3901U (de)
WO (1) WO2002098413A2 (de)
ZA (1) ZA200309099B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) * 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US7588786B2 (en) * 2001-11-14 2009-09-15 Jarrow Formulas, Inc. Eutectic-based self-nanoemulsified drug delivery system
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
PT1673359E (pt) * 2003-09-12 2009-10-06 Ranbaxy Lab Ltd Processo para a preparação de formas cristalinas de orlistat
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
EP2034983A1 (de) * 2006-06-27 2009-03-18 Lipid Nutrition B.V. Verwendung einer mehrfach ungesättigten fettsäureverbindung
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
US20100196464A1 (en) * 2007-09-17 2010-08-05 Dr. Reddy's Laboratories Limited Orlistat pharmaceutical formulations
EP2219614A1 (de) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmazeutische zusammensetzung von orlistat
US8298583B2 (en) * 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
KR200449701Y1 (ko) * 2008-08-21 2010-08-02 한복순 월풀욕조의 잔물 제거장치
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
KR101593539B1 (ko) * 2015-07-03 2016-02-15 고려대학교 산학협력단 지방조직 중성지질 분해 효능을 가지는 아젤라산 조성물
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN109310646A (zh) 2016-05-05 2019-02-05 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US11931330B2 (en) 2018-02-20 2024-03-19 Korea University Research And Business Foundation Composition for promoting skeletal muscle activity via induction of mitochondrial biogenesis comprising of azelaic acid as an active ingredient
US10786475B2 (en) 2018-02-20 2020-09-29 Korea University Research And Business Foundation Method for preventing, treating, or improving fatty liver by administering effective amounts of azelaic acid to a subject
CN108354910A (zh) * 2018-05-17 2018-08-03 安士制药（中山）有限公司 一种西甲硅油软胶囊
BR112021010407A2 (pt) * 2018-12-06 2021-08-24 International Flavors & Fragrances Inc. Artigo de consumo, e, métodos para realçar a doçura ou sensação bucal de um artigo de consumo e para mascarar um sabor proteináceo desagradável de um artigo de consumo
WO2020118005A1 (en) * 2018-12-06 2020-06-11 International Flavors & Fragrances Inc. Traumatic acid compositions and methods for taste modulation
WO2021023857A1 (en) * 2019-08-08 2021-02-11 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
DE3217071A1 (de) 1982-05-06 1983-11-10 Rüdiger Dr. 6365 Rosbach Gröning Arzneimittel fuer die perorale applikation mit verbesserter biologischer verfuegbarkeit der wirkstoffe
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
FI912955A (fi) 1990-06-25 1991-12-26 Res Found Mental Hygiene Antimikroba fettsyrasammansaettningar.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
JP2682353B2 (ja) * 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
JPH1081621A (ja) * 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
DE19739031A1 (de) 1997-09-05 1999-03-11 Suwelack Nachf Dr Otto Mittel zur peroralen Verabreichung, seine Herstellung und Verwendung
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
DK1105122T3 (da) 1998-08-14 2005-08-08 Hoffmann La Roche Pharmaceutical compositions containing lipase inhibitors
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6348492B1 (en) 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
CA2358921A1 (en) 1999-10-29 2001-05-10 John Jason Gentry Mullins Oxetanone derivatives
AU1460801A (en) * 1999-11-04 2001-05-14 Patrick J Kinlen Cholesterol reducing sterol compositions, preparation and method of use

Also Published As

Publication number Publication date
ES2292782T3 (es) 2008-03-16
GT200200105A (es) 2003-02-26
US6730319B2 (en) 2004-05-04
JP4558313B2 (ja) 2010-10-06
DK1399153T3 (da) 2008-01-07
AU2002319189B2 (en) 2005-08-18
KR100613946B1 (ko) 2006-08-18
JP2004532272A (ja) 2004-10-21
AR037490A1 (es) 2004-11-17
PT1399153E (pt) 2007-12-31
DE60222898T2 (de) 2008-07-24
EP1399153B1 (de) 2007-10-10
MXPA03011041A (es) 2004-03-19
BR0210267A (pt) 2004-07-20
ZA200309099B (en) 2005-05-25
EP1399153A2 (de) 2004-03-24
WO2002098413A2 (en) 2002-12-12
US20030039686A1 (en) 2003-02-27
CN1514726A (zh) 2004-07-21
KR20040010681A (ko) 2004-01-31
CA2448035C (en) 2009-11-03
UY27320A1 (es) 2003-02-28
PE20030262A1 (es) 2003-03-19
WO2002098413A3 (en) 2003-02-27
ATE375155T1 (de) 2007-10-15
UY3901U (es) 2002-07-31
PA8546501A1 (es) 2003-01-24
CN1514726B (zh) 2010-10-06
CA2448035A1 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
DE60222898D1 (de) Orlistat und eine fettsäure oder eines ihrer salze enthaltende pharmazeutische zusammensetzung
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
ATE468324T1 (de) Pharmazeutische zusammensetzung
ATA1292000A (de) Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EE200200021A (et) Asendamatuid rasvhappeid ja homotsüsteiini taset alandavaid aineid sisaldavad farmatseutilised ühendid ja toidulisandid
DE60111769D1 (de) Flüssige pharmazeutische formulierungen mit verbesserter oraler veträglichkeit
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
ITTO20010008A0 (it) Formulazione farmaceutica
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
DK1438040T3 (da) Farmaceutiske sammensætninger indeholdende mycophenolsyre eller et mycophenolsalt
EE200200393A (et) Glüburiidi ravimkoostis
DE69900561D1 (de) Pharmazeutische Zusammensetzungen enthaltend Mupirocin
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE50213084D1 (de) Kosmetische und/oder pharmazeutische zubereitungen
HUP0400801A3 (en) Pharmaceutical compositions containing bile acid or bile salt fatty acid conjugates and their use
ATE356622T1 (de) Einen lipase-inhibitor und einen saccharosefettsäuremonoester enthaltende pharmazeutische zusammensetzung
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
DE60129238D1 (de) Pharmazeutische zusammensetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE222586T1 (de) Benzolsulfonamidderivate und verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE60234586D1 (de) Nsaid-formulierung enthaltend eine granulöse zusammensetzung und eine extragranulöse zusammensetzung
ATE290543T1 (de) Pharmazeutische zusammensetzungen mit oligosacchariden und deren herstellung
DE59902845D1 (de) Ribonuclein- oder desoxyribonucleinsaüren enthältendes kosmetische oder pharmazeutische mittel
ATE332140T1 (de) Pharmazeutische zusammensetzungen, welche steroidische strukturen enthalten, und deren verwendungen
DE10291905D2 (de) Pharmazeutische Zusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition